Overall, Merck and Harvard researchers calculated that they could rule out with 95% certainty the possibility that anacetrapib could cause the 25% increase in heart attacks and other cardiovascular events seen with torcetrapib.

FORBES: Merck's New Drug Could End The Stent Business

That scenario will make near-term paralysis a certainty and future economic catastrophe a distinct possibility.

FORBES: U.S. Voters Are The Ultimate Super Committee